Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: An integrated analysis

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 12, Issue 3, 2007, Pages 205-212

  Weerakkody, Govinda J ^a   Jakubowski, Joseph A ^a   Brandt, John T ^a   Payne, Christopher D ^a   Naganuma, Hideo ^b   Winters, Kenneth J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

ADP; Clopidogrel; P2Y12; Platelet aggregation; Prasugrel; Resistance; Thienopyridines

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PRASUGREL;

ADULT; AGED; ARTICLE; BAYES THEOREM; FEMALE; HUMAN; HUMAN EXPERIMENT; LOADING DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RESPONSE VARIABLE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT RESPONSE;

ADENOSINE DIPHOSPHATE; ADOLESCENT; ADULT; AGED; BAYES THEOREM; CLINICAL TRIALS, PHASE I; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 34548151179     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248407304731     Document Type: Article

References (33)

1. Storey RF Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des. 2006 ; 12: 1255-1259.
2. Barragan P., Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv. 2003 ; 59: 295-302.
3. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003 ; 107: 2908-2913.
4. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004 ; 109: 166-171.
5. Lepantalo A., Virtanen KS, Heikkila J., Wartiovaara U., Lassila R. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J. 2004 ; 25: 476-483.
6. Angiolillo DJ, Fernandez-Ortiz A., Bernardo E., et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res. 2005 ; 115: 101-108.
7. Von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005 ; 112: 2946-2950.
8. Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005 ; 111: 2560-2564.
9. Smith SM, Judge HM, Peters G., et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets. 2006 ; 17: 250-258.
10. Muller I., Besta F., Schulz C., Massberg S., Schomig A., Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003 ; 89: 783-787.
11. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004 ; 109: 3171-3175.
12. Hochholzer W., Trenk D., Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006 ; 48: 1742-1750.
13. Cuisset T., Frere C., Quilici J., et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006 ; 4: 542-549.
14. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005 ; 111: 3366-3373.
15. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the Trial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006 ; 152: 627-635.
16. Sugidachi A., Asai F., Ogawa T., et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000 ; 129: 1439-1446.
17. Jakubowksi JA, Payne CD, Brandt JT, et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol. 2006 ; 47: 377-384.
18. Jakubowski JA, Matsushima N., Asai F., et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol. 2007 ; 63: 421-430.
19. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite. Am Heart J. 2007 ; 153 :66.e9-16.
20. Savi P., Combalbert J., Gaich C., et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 2006 ; 72: 313-317.
21. Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006 ; 34: 600-607.
22. Weerakoddy GJ, Brandt JT, Payne CD, Jakubowski JA, Naganuma H., Winters KJ Clopidogrel poor responders: an objective definition based on Bayesian classification. Platelets. (In press).
23. Jernberg T., Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006 ; 27: 1166-1173.
24. Bates ER, Lau WC, Bleske BE Loading, pretreatment, and interindividual variability issues with clopidogrel dosing. Circulation. 2005 ; 111: 2557-2559.
25. Gurbel PA, Tantry US Drug insight: clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med. 2006 ; 3: 387-395.
26. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 ; 81: 735-741.
27. Gurbel PA, Bliden KP, Samara W., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol. 2005 ; 46: 1827-1832.
28. Muller I., Seyfarth M., Rudiger S., et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001 ; 85: 92-93.
29. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US Clopidogrel loading with eptifibatide to arrest the reactivity of platelets-Results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study. Circulation. 2005 ; 111: 1153-1159.
30. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005 ; 45: 1392-1396.
31. Montalescot G., Sideris G., Meuleman C., et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006 ; 48: 931-938.
32. Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol. (In press).
33. Jakubowski JA, Payne CD, Weerakkoddy GJ, et al. Dose-dependent inhibition of platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol. 2007 ; 49: 167-173.